Cleaved Galectin-3 Detection for Active MMP Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic tools lack the ability to differentiate between pro- and active matrix metalloproteinases (MMPs) in cancer patients, making it difficult to assess the efficacy of treatments targeting MMPs, particularly in distinguishing between latent and active forms of MMP-2 and MMP-9.
Innovation Solution
Development of anti-MMP-2/9 and anti-galectin-3 monoclonal and polyclonal antibodies to visualize cleaved galectin-3 in tissues, serving as a surrogate marker for active MMPs, along with methods to inhibit tumor angiogenesis using synthetic MMP inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic tools are used to detect MMPs in cancer patients, then MMP presence can be detected, but the ability to differentiate between pro- and active MMP forms is lost
Solution Approach 1:
The patent uses galectin-3 as an intermediary substrate that is specifically cleaved by active MMP-2 and MMP-9. By detecting the presence of cleaved galectin-3 fragments rather than the intact protein, the method serves as an indirect but reliable marker for active MMP presence, resolving the contradiction between detection capability and differentiation precision
Solution Approach 2:
The patent replaces complex direct detection methods for MMP activity with a simpler indirect detection system. Instead of directly measuring MMP activity or form, the method substitutes the detection of MMP substrate cleavage products (galectin-3 fragments) which provides equivalent information with greater precision and ease
2Reliability
If MMP inhibitors are used to treat cancer, then tumor angiogenesis may be inhibited, but lack of diagnostic tools prevents assessment of treatment efficacy
Solution Approach 1:
The patent establishes a feedback mechanism for monitoring MMP inhibitor treatment efficacy. By detecting changes in cleaved galectin-3 levels in patient samples, clinicians can assess whether MMP activity is being successfully inhibited by the treatment, providing real-time feedback on treatment response and allowing for adaptive treatment adjustments
Solution Approach 2:
The patent substitutes complex treatment monitoring systems with a simpler diagnostic approach based on galectin-3 cleavage detection. This substitution enables reliable assessment of treatment efficacy without requiring complex direct measurement of MMP activity or tumor angiogenesis parameters
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the identification of active MMPs in cancer tissues, predicting the effectiveness of MMP inhibitors and aiding in the diagnosis and prognosis of cancer, particularly in breast cancer, by providing a simple, rapid, and reliable method to assess MMP activity.
Implementation Method 1
Matrix metalloproteinases (MMPs) are a family of Zn-dependent proteinases that can be divided into 5 groups based on substrate specificity. They remodel extra-cellular matrix (ECM) components and cleave a broad range of cell surface proteins resulting in substrate degradation
Data Source
AI summary
Provided are differential antibodies recognizing the cleaved and non-cleaved forms of matrix metalloproteinases (MMPs), and methods of using the antibodies as surrogate diagnostic markers for the presence of active MMPs in cancer, such as growing breast cancers.